AffiliationDepartment of Endocrinology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractKnowledge of the interaction between growth hormone (GH) and the growth hormone receptor (GHR) has led to the rational design of a GHR antagonist. An analogue of GH able to block the action of GH at the cellular level offers greater specificity of effect compared with current medical therapies and is not dependent on tumour characteristics. This chapter reviews the interaction between GH and the GHR, and discusses the outstanding issues regarding GHR antagonist therapy in acromegaly.
CitationGrowth hormone receptor antagonists therapy for acromegaly. 1999, 13 (3):419-30 Baillieres Best Pract Res Clin Endocrinol Metab
JournalBaillière's Best Practice & Research. Clinical Endocrinology & Metabolism
- Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
- Authors: Parkinson C, Trainer PJ
- Issue date: 2000 Apr
- Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
- Authors: Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ
- Issue date: 2002 Oct
- Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
- Authors: Drake WM, Parkinson C, Besser GM, Trainer PJ
- Issue date: 2001 Nov
- Experience with pegvisomant in the treatment of acromegaly.
- Authors: Drake WM
- Issue date: 2001 Jun
- Lessons learned from studies with the growth hormone receptor.
- Authors: Kopchick JJ
- Issue date: 2016 Jun